Biopharmaceutical/Oncology - Immuno-oncology and target protein degradation
Strategic Profile
Plinabulin's mechanism as a dendritic cell maturation agent supports both anti-cancer activity and immune modulation, offering a unique approach to resensitizing tumors resistant to checkpoint inhibitors. BeyondSpring co-founded SEED Therapeutics (38% ownership) which closed a $30M Series A-3 with FDA and NMPA IND clearance.
Cyborg Score Rationale
Plinabulin demonstrated positive Phase 3 efficacy in NSCLC with meaningful OS benefits and 3-month survival advantage in non-squamous subgroups, supporting regulatory pathway advancement. However, Q3 2025 financials show minimal cash runway with $12.5M and monthly burn of $1.7M from continuing operations, creating execution risk.
Top Insights
60% of NSCLC patients develop resistance to anti-PD-(L)1 therapy with no new treatments approved in a decade, representing significant unmet need.
Plinabulin markedly reduced docetaxel-induced grade 4 neutropenia (3.9% vs 26.5%), addressing a major chemo side effect.
SEED subsidiary advances targeted protein degradation via proprietary RITE3 platform with strategic partnerships with Eli Lilly and Eisai.
BeyondSpring plans global Phase 3 DUBLIN-4 trial following End-of-Phase 2 FDA meeting.
Named Competitors
Pembrolizumab + Chemotherapy — PD-1 checkpoint inhibitor with docetaxel for NSCLC
Nivolumab + Ipilimumab — Dual checkpoint inhibitor combination for cancer
(December 2025) Post-hoc DUBLIN-3 analyses showed plinabulin plus docetaxel achieved 15.8 vs 11.7 month median OS in EGFR WT NSCLC after PD-1/L1 progression
(August 2025) Q2 2025 financial results showed improved net loss of $1.9M vs $2.7M prior year; announced Med publication on plinabulin dendritic cell activation
(November 2025) Q3 2025 results announced with Phase 2 NSCLC cohort showing 85% disease control rate and 79% 12-month OS
Open the full interactive BeyondSpring Inc. report
Strategic research, analyst-debate audio, full Cyborg Score breakdown across 11 dimensions, and saved-company audio playlists.